Dr. Andrew Hendifar retweeted
Replying to @AACI_Cancer
@AACI_Cancer recently highlighted 2 @CedarsSinai studies ➡️ our high-dose L-Gln phase I trial @NatureCancer & physical activity benefit on fatigue & #QoL in #CRC @JNCCN by Dr. Figueiredo & ⭐️fellow now @cityofhope #GIonc faculty @LouisaLiu131
aaci-cancer.org/aaci-update-…
@OncoAlert
Dr. Andrew Hendifar retweeted
1/🧵
IITs/ISTs are often a labor of love. Proud to share that our phase I GlutaPanc trial testing the feasibility of pairing @FDA approved high-dose L-glutamine (L-Gln) + #1L gem/nab-paclitaxel (GA) in #mPDAC was published in @NatureCancer
nature.com/articles/s43018-0…
@OncoAlert – at Beverly Hills, CA
Dr. Andrew Hendifar retweeted
Until now, physicians using AI in clinic had to assemble the patient’s context themselves. Allergies, comorbidities, medications, prior procedures, copy-pasted in from the chart.
Today we’re announcing a partnership with @CedarsSinai. OpenEvidence now works directly inside Epic, drawing on the patient’s full record and interpreting the medical literature through the lens of that specific patient.
Cedars-Sinai is the first academic health system to deploy patient-aware clinical intelligence at enterprise scale. The clinician asks a complex question in natural language. The answer reflects both the best available evidence and the patient in front of them.
Patient data is never stored after the clinical session or used for any other purpose.
Attention to 2026 ASCO Gastrointestinal Cancers Symposium attendees! ‼️
Check out poster L8 at Poster Session B today at #GI26 to learn about an #AI biomarker that is predictive of beneficial first-line chemo regimens for patients with #pancreaticcancer. 🧬
Presented by PanCAN Scientific and Medical Advisory Board (SMAB) Member and Scientific Advisor of @ValarLabs, @DrHendifar.
Data from PanCAN's Know Your Tumor program from our SPARK platform was used as a validation dataset in this important study. asco.org/abstracts-presentat…
Dr. Andrew Hendifar retweeted
“Use of a computational histology artificial intelligence-powered
predictive biomarker for chemotherapy selection in advanced
pancreatic cancer patients from a multi-institutional cohort including
two prospective studies.” Research by: @DrHendifar, @VisweshKrishna, @BarbaraGrnwald, @mnoel3232, @PancPathologist, Jennifer J. Knox and others at @ASCO #GI26. @PanCAN
Very proud of the team for putting this together. @DrArsenOsipov @jgong15 @AbrahamLevi2709 @cscancer Growth Differentiation Factor 15 Serum Levels in Pancreatic Cancer | JCO Oncology Advances ascopubs.org/doi/10.1200/OA-…
Dr. Andrew Hendifar retweeted
Real-world analysis in @JCOPO_ASCO of a large @PanCAN @Perthera #KnowYourTumor cohort ➡️ effects of #KRAS variants on survival and therapy response in #PDAC led by @DrHendifar @DrArsenOsipov @SriGaddamMD and team @CedarsSinai @MPishvaian
ascopubs.org/doi/10.1200/PO-…
@OncoAlert
Dr. Andrew Hendifar retweeted
Huge congrats to @CSCancerCenter 2nd yr heme/onc fellow Dr. Louisa Liu for her 2025 @ConquerCancerFd #YIA 🙌❗️❗️Way to represent @CedarsSinai. Proud to serve as her mentor for this award. As a former class of 2022 @ASCO #CCF #CDA recipient, I know how impactful this award will be
Congratulations to this year’s class of Conquer Cancer grant and award recipients! Are you one of them? Tell us in the comments! We can't wait to celebrate with you at #ASCO25. Full list of recipients: brnw.ch/21wSR0A
@ASCO
Morning run with @NoahMerrin, And Hyung Kim @CedarsSinai 2025 Faculty retreat. Stopping for pics is the only way to keep up with Zab Mosenifar. @CedarsSinaiMed
Dr. Andrew Hendifar retweeted
Today is #WorldCancerDay thank you @KTLA for this interview & raising cancer awareness @LuParker @glenwalkerktla
@CSCancerCenter @OncoAlert @Larvol @OPENoncology @oncodaily @CParkMD @medicalwatchBC @MOASC_Office @OncoReporte @LinksCancer @OncBrothers
ktla.com/video/doctor-jun-go…
Dr. Andrew Hendifar retweeted
We have compared the performance ctDNA by Natera vs. imaging in curatively resected colorectal cancer on surveillance. Signatera missed 31% of recurrences (+ imaging and negative Signatera). Largest study of comparative strategies. jamanetwork.com/journals/jam…
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer | New England Journal of Medicine nejm.org/doi/full/10.1056/NE….
Dual checkpoint inhibition with unprecedented outcomes in MSI-High colorectal cancer. A new standard of care.
Pancreatic Cancer Surge May Be Less Worrisome Than It Seemed - The New York Times. nytimes.com/2024/11/18/healt…
Understanding and Treating Pancreatic Cancer Cachexia | Blog | AACR - goo.gl/alerts/gCyikP #GoogleAlerts. Addressing cancer associated weight loss will become a pillar of cancer care in the near future. #PancreaticCancer @CSCancerCenter
RMC-9805 Triggers Tumor Regressions in KRAS G12D–Mutant Pancreatic Cancer onclive.com/view/rmc-9805-tr… via @onclive
As this novel approach to improving weight and performance continues to develop, cancer patients will finally get an opportunity to look and feel like their “old selves”. A great moment for cancer care. @myESMO @NEJM @pfizer
Presented at #ESMO24:
The monoclonal antibody ponsegromab increased weight, improved appetite, and allowed an increase in physical activity in patients with cancer who had lost more than 5% of body weight in the past 6 months.
Full trial results: nej.md/3XE645a
Dr. Andrew Hendifar retweeted
🚨🚨Hot off the press @NEJM
In a randomized Ph II Ponsegromab, an anti-GDF15 mAB, increased weight gain, overall physical activity and reduced cachexia symptoms in patients with #cachexia and ⬆️ GDF-15
nejm.org/doi/full/10.1056/NE…
High frequency of germline variants in CFTR identified in PDAC patient... sciencedirect.com/science/ar…. interesting finding in pdac patients who had testing for pancreatitis associated germline variants. @DrArsenOsipov
Dr. Andrew Hendifar retweeted
The (almost) full program is now online with an amazing lineup of speakers!
#AACRPan24
@EileenMOReilly @ManciasLab @DrJashDatta @TeresaZimmers @DrHendifar @JanowitzTobias @wantong_yao @MaraShermanLab @KenOliveLab @andrewaguirremd @cjder23 @bryant_kl @pratt_ed @mggoggins @ChristieTowers @Cosimo_Commisso @Chiolaboratory @nada_kalaany and those not on Twitter. See you all in Boston!
aacr.org/meeting/aacr-specia…
@AACR #PancreaticCancer
Abstract submissions are now open for the @AACR special conference on #PancreaticCancer #AACRPan24
Outline of proposed program below:
aacr.org/meeting/aacr-specia…






















